Liminal BioSciences Stock Falls on Scrapping Further Development of Fezagepras

by Vandana Singh, Benzinga Editor

June 1, 2021 8:07 AM | 1 min read |

Based on interim pharmacokinetics (PK) results from the ongoing multiple ascending dose study Liminal BioSciences Inc LMNL has decided not to move fezagepras into a Phase 2 study in Idiopathic Pulmonary Fibrosis and a Phase 1a/2b study in Hypertriglyceridemia.
The Company is evaluating the interim PK results.
Once the study is complete, the Company expects that a full analysis of the complete PK data set from the phase 1 study will help determine the choice of any other potential indication(s) for further development of fezagepras.
No dose-limiting adverse events or other potential safety signals have been observed.
Price Action: LMNL shares dropped 5.88% at $4.16 during the premarket session on the last check Tuesday.